These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20737625)

  • 1. Kinetics of aspartic acid isomerization and enantiomerization in model aspartyl tripeptides under forced conditions.
    Conrad U; Fahr A; Scriba GK
    J Pharm Sci; 2010 Oct; 99(10):4162-73. PubMed ID: 20737625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capillary electrophoretic study of the degradation pathways and kinetics of the aspartyl model tetrapeptide Gly-Phe-Asp-GlyOH in alkaline solution.
    Brückner C; Imhof D; Scriba GK
    J Pharm Biomed Anal; 2013 Mar; 76():96-103. PubMed ID: 23298912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isomerization and epimerization of the aspartyl tetrapeptide Ala-Phe-Asp-GlyOH at pH 10-A CE study.
    Brückner C; Bunz SC; Imhof D; Neusüss C; Scriba GK
    Electrophoresis; 2013 Sep; 34(18):2666-73. PubMed ID: 23533053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation kinetics of an aspartyl-tripeptide-derived diketopiperazine under forced conditions.
    Brückner C; Fahr A; Imhof D; Scriba GK
    J Pharm Sci; 2012 Nov; 101(11):4178-90. PubMed ID: 22899465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capillary electrophoresis analysis of hydrolysis, isomerization and enantiomerization of aspartyl model tripeptides in acidic and alkaline solution.
    De Boni S; Scriba GK
    J Pharm Biomed Anal; 2007 Jan; 43(1):49-56. PubMed ID: 16846713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of degradation products of aspartyl tripeptides by capillary electrophoresis-tandem mass spectrometry.
    De Boni S; Neusüss C; Pelzing M; Scriba GK
    Electrophoresis; 2003 Mar; 24(5):874-82. PubMed ID: 12627450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capillary electrophoresis analysis of the degradation of the aspartyl tripeptide Phe-Asp-GlyOH at pH 2.0 and 7.4 under forced conditions.
    Conrad U; Taichrib A; Neusüss C; Scriba GK
    J Pharm Biomed Anal; 2010 Feb; 51(3):640-8. PubMed ID: 19875263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of aspartyl peptide degradation products by high-performance liquid chromatography and high-performance liquid chromatography-mass spectrometry.
    De Boni S; Oberthür C; Hamburger M; Scriba GK
    J Chromatogr A; 2004 Jan; 1022(1-2):95-102. PubMed ID: 14753775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of the competitive reactions of isomerization and peptide bond cleavage at l-α- and d-β-aspartyl residues in an αA-crystallin fragment.
    Aki K; Okamura E
    J Pept Sci; 2017 Jan; 23(1):28-37. PubMed ID: 27905156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues.
    Güttler BH; Cynis H; Seifert F; Ludwig HH; Porzel A; Schilling S
    Amino Acids; 2013 Apr; 44(4):1205-14. PubMed ID: 23344882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of rate constants for β-linkage isomerization of three specific aspartyl residues in recombinant human αA-crystallin protein by reversed-phase HPLC.
    Sadakane Y; Fujii N; Nakagomi K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Nov; 879(29):3240-6. PubMed ID: 21470922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of the cyclic imide in alternate degradation pathways for asparagine-containing peptides and proteins.
    Dehart MP; Anderson BD
    J Pharm Sci; 2007 Oct; 96(10):2667-85. PubMed ID: 17518358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of isomerization and inversion of aspartate 58 of αA-crystallin peptide mimics under physiological conditions.
    Aki K; Fujii N; Fujii N
    PLoS One; 2013; 8(3):e58515. PubMed ID: 23505525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous racemization and isomerization at specific aspartic acid residues in alpha B-crystallin from the aged human lens.
    Fujii N; Ishibashi Y; Satoh K; Fujino M; Harada K
    Biochim Biophys Acta; 1994 Feb; 1204(2):157-63. PubMed ID: 8142454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation.
    Geiger T; Clarke S
    J Biol Chem; 1987 Jan; 262(2):785-94. PubMed ID: 3805008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of stereoisomers and isoforms of a tryptic heptapeptide fragment of human growth hormone and analysis by reverse-phase HPLC and capillary electrophoresis.
    Vinther A; Holm A; Høeg-Jensen T; Jespersen AM; Klausen NK; Christensen T; Sørensen HH
    Eur J Biochem; 1996 Jan; 235(1-2):304-9. PubMed ID: 8631346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the pathway and kinetics of aspartic acid isomerization in peptide mapping methods for monoclonal antibodies.
    Kuang J; Tao Y; Song Y; Chemmalil L; Mussa N; Ding J; Li ZJ
    Anal Bioanal Chem; 2021 Mar; 413(8):2113-2123. PubMed ID: 33543314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide.
    Oliyai C; Borchardt RT
    Pharm Res; 1993 Jan; 10(1):95-102. PubMed ID: 8430066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of structural alterations of L-Asp and L-Asn residues in peptides related to neuronal diseases by reversed-phase high-performance liquid chromatography.
    Sadakane Y; Konoha K; Kawahara M; Nakagomi K
    Chem Biodivers; 2010 Jun; 7(6):1371-9. PubMed ID: 20564556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical pathways of peptide degradation. VI. Effect of the primary sequence on the pathways of degradation of aspartyl residues in model hexapeptides.
    Oliyai C; Borchardt RT
    Pharm Res; 1994 May; 11(5):751-8. PubMed ID: 8058648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.